|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LPIN2 |
Gene summary for LPIN2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LPIN2 | Gene ID | 9663 |
| Gene name | lipin 2 | |
| Gene Alias | LPIN2 | |
| Cytomap | 18p11.31 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | Q92539 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9663 | LPIN2 | LZE7T | Human | Esophagus | ESCC | 1.13e-02 | 2.12e-01 | 0.0667 |
| 9663 | LPIN2 | LZE24T | Human | Esophagus | ESCC | 3.26e-02 | 8.68e-02 | 0.0596 |
| 9663 | LPIN2 | P1T-E | Human | Esophagus | ESCC | 1.04e-02 | 3.95e-01 | 0.0875 |
| 9663 | LPIN2 | P2T-E | Human | Esophagus | ESCC | 7.41e-16 | 4.27e-01 | 0.1177 |
| 9663 | LPIN2 | P4T-E | Human | Esophagus | ESCC | 4.70e-13 | 3.38e-01 | 0.1323 |
| 9663 | LPIN2 | P5T-E | Human | Esophagus | ESCC | 4.69e-06 | 5.71e-02 | 0.1327 |
| 9663 | LPIN2 | P8T-E | Human | Esophagus | ESCC | 1.43e-10 | 2.25e-01 | 0.0889 |
| 9663 | LPIN2 | P9T-E | Human | Esophagus | ESCC | 1.14e-11 | 2.64e-01 | 0.1131 |
| 9663 | LPIN2 | P10T-E | Human | Esophagus | ESCC | 9.71e-22 | 4.08e-01 | 0.116 |
| 9663 | LPIN2 | P11T-E | Human | Esophagus | ESCC | 1.87e-07 | 3.30e-01 | 0.1426 |
| 9663 | LPIN2 | P16T-E | Human | Esophagus | ESCC | 3.77e-05 | 1.59e-01 | 0.1153 |
| 9663 | LPIN2 | P21T-E | Human | Esophagus | ESCC | 1.64e-13 | 3.08e-01 | 0.1617 |
| 9663 | LPIN2 | P22T-E | Human | Esophagus | ESCC | 1.03e-04 | 1.50e-01 | 0.1236 |
| 9663 | LPIN2 | P23T-E | Human | Esophagus | ESCC | 2.99e-15 | 7.09e-01 | 0.108 |
| 9663 | LPIN2 | P24T-E | Human | Esophagus | ESCC | 3.14e-03 | 5.19e-02 | 0.1287 |
| 9663 | LPIN2 | P26T-E | Human | Esophagus | ESCC | 2.49e-26 | 5.15e-01 | 0.1276 |
| 9663 | LPIN2 | P27T-E | Human | Esophagus | ESCC | 2.07e-13 | 3.47e-01 | 0.1055 |
| 9663 | LPIN2 | P31T-E | Human | Esophagus | ESCC | 1.62e-14 | 3.59e-01 | 0.1251 |
| 9663 | LPIN2 | P32T-E | Human | Esophagus | ESCC | 4.58e-05 | 1.27e-01 | 0.1666 |
| 9663 | LPIN2 | P37T-E | Human | Esophagus | ESCC | 8.60e-09 | 2.60e-01 | 0.1371 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00713755 | Liver | NAFLD | cellular response to peptide hormone stimulus | 65/1882 | 290/18723 | 3.95e-10 | 9.62e-08 | 65 |
| GO:00442425 | Liver | NAFLD | cellular lipid catabolic process | 52/1882 | 214/18723 | 1.15e-09 | 2.17e-07 | 52 |
| GO:19016536 | Liver | NAFLD | cellular response to peptide | 71/1882 | 359/18723 | 1.82e-08 | 2.09e-06 | 71 |
| GO:00328695 | Liver | NAFLD | cellular response to insulin stimulus | 47/1882 | 203/18723 | 3.60e-08 | 3.63e-06 | 47 |
| GO:00066413 | Liver | NAFLD | triglyceride metabolic process | 29/1882 | 100/18723 | 9.51e-08 | 7.62e-06 | 29 |
| GO:00160426 | Liver | NAFLD | lipid catabolic process | 63/1882 | 320/18723 | 1.35e-07 | 1.02e-05 | 63 |
| GO:00434346 | Liver | NAFLD | response to peptide hormone | 76/1882 | 414/18723 | 1.51e-07 | 1.09e-05 | 76 |
| GO:00328685 | Liver | NAFLD | response to insulin | 53/1882 | 264/18723 | 6.99e-07 | 3.95e-05 | 53 |
| GO:00066392 | Liver | NAFLD | acylglycerol metabolic process | 32/1882 | 128/18723 | 8.82e-07 | 4.60e-05 | 32 |
| GO:00066382 | Liver | NAFLD | neutral lipid metabolic process | 32/1882 | 129/18723 | 1.06e-06 | 5.35e-05 | 32 |
| GO:00464863 | Liver | NAFLD | glycerolipid metabolic process | 66/1882 | 392/18723 | 1.94e-05 | 5.52e-04 | 66 |
| GO:00163115 | Liver | NAFLD | dephosphorylation | 69/1882 | 417/18723 | 2.27e-05 | 6.23e-04 | 69 |
| GO:00194322 | Liver | NAFLD | triglyceride biosynthetic process | 13/1882 | 42/18723 | 1.60e-04 | 2.94e-03 | 13 |
| GO:00450174 | Liver | NAFLD | glycerolipid biosynthetic process | 43/1882 | 252/18723 | 3.83e-04 | 5.73e-03 | 43 |
| GO:00464601 | Liver | NAFLD | neutral lipid biosynthetic process | 13/1882 | 50/18723 | 1.04e-03 | 1.22e-02 | 13 |
| GO:00464631 | Liver | NAFLD | acylglycerol biosynthetic process | 13/1882 | 50/18723 | 1.04e-03 | 1.22e-02 | 13 |
| GO:000663112 | Liver | Cirrhotic | fatty acid metabolic process | 165/4634 | 390/18723 | 1.29e-14 | 1.26e-12 | 165 |
| GO:004428211 | Liver | Cirrhotic | small molecule catabolic process | 151/4634 | 376/18723 | 2.20e-11 | 1.34e-09 | 151 |
| GO:001605411 | Liver | Cirrhotic | organic acid catabolic process | 104/4634 | 240/18723 | 1.91e-10 | 9.53e-09 | 104 |
| GO:004639511 | Liver | Cirrhotic | carboxylic acid catabolic process | 102/4634 | 236/18723 | 3.41e-10 | 1.63e-08 | 102 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa041505 | Esophagus | ESCC | mTOR signaling pathway | 98/4205 | 156/8465 | 5.81e-04 | 1.95e-03 | 9.97e-04 | 98 |
| hsa0415013 | Esophagus | ESCC | mTOR signaling pathway | 98/4205 | 156/8465 | 5.81e-04 | 1.95e-03 | 9.97e-04 | 98 |
| hsa04936 | Liver | Cirrhotic | Alcoholic liver disease | 60/2530 | 142/8465 | 1.07e-03 | 5.85e-03 | 3.61e-03 | 60 |
| hsa049361 | Liver | Cirrhotic | Alcoholic liver disease | 60/2530 | 142/8465 | 1.07e-03 | 5.85e-03 | 3.61e-03 | 60 |
| hsa049362 | Liver | HCC | Alcoholic liver disease | 89/4020 | 142/8465 | 1.73e-04 | 8.53e-04 | 4.75e-04 | 89 |
| hsa041502 | Liver | HCC | mTOR signaling pathway | 95/4020 | 156/8465 | 4.70e-04 | 1.99e-03 | 1.11e-03 | 95 |
| hsa049363 | Liver | HCC | Alcoholic liver disease | 89/4020 | 142/8465 | 1.73e-04 | 8.53e-04 | 4.75e-04 | 89 |
| hsa0415011 | Liver | HCC | mTOR signaling pathway | 95/4020 | 156/8465 | 4.70e-04 | 1.99e-03 | 1.11e-03 | 95 |
| hsa049364 | Lung | IAC | Alcoholic liver disease | 29/1053 | 142/8465 | 4.45e-03 | 2.07e-02 | 1.37e-02 | 29 |
| hsa0493611 | Lung | IAC | Alcoholic liver disease | 29/1053 | 142/8465 | 4.45e-03 | 2.07e-02 | 1.37e-02 | 29 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LPIN2 | SNV | Missense_Mutation | novel | c.2626N>C | p.Glu876Gln | p.E876Q | Q92539 | protein_coding | deleterious(0) | probably_damaging(0.914) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| LPIN2 | SNV | Missense_Mutation | rs201325845 | c.1489N>A | p.Glu497Lys | p.E497K | Q92539 | protein_coding | deleterious(0.03) | possibly_damaging(0.572) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| LPIN2 | SNV | Missense_Mutation | c.1231C>A | p.Leu411Ile | p.L411I | Q92539 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| LPIN2 | SNV | Missense_Mutation | c.898N>C | p.Val300Leu | p.V300L | Q92539 | protein_coding | tolerated(0.09) | benign(0.248) | TCGA-E9-A1RF-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
| LPIN2 | SNV | Missense_Mutation | rs201325845 | c.1489N>A | p.Glu497Lys | p.E497K | Q92539 | protein_coding | deleterious(0.03) | possibly_damaging(0.572) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
| LPIN2 | deletion | Frame_Shift_Del | c.706_710delNNNNN | p.Pro236AspfsTer5 | p.P236Dfs*5 | Q92539 | protein_coding | TCGA-BH-A0B3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |||
| LPIN2 | SNV | Missense_Mutation | rs749727482 | c.839N>A | p.Arg280Gln | p.R280Q | Q92539 | protein_coding | tolerated(0.18) | benign(0.165) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| LPIN2 | SNV | Missense_Mutation | novel | c.1333N>A | p.Gln445Lys | p.Q445K | Q92539 | protein_coding | tolerated(0.08) | possibly_damaging(0.627) | TCGA-C5-A7CK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| LPIN2 | SNV | Missense_Mutation | novel | c.428N>A | p.Thr143Lys | p.T143K | Q92539 | protein_coding | tolerated(0.69) | benign(0) | TCGA-EK-A2H0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| LPIN2 | SNV | Missense_Mutation | rs753664055 | c.2435G>A | p.Arg812His | p.R812H | Q92539 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-FU-A3WB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |